T cell repertoire changes predictive of anti-CTLA-4 cancer immunotherapy outcome revealed
Sequenta, Inc. today announced publication of a study done in collaboration with researchers from UCSF and UCLA that used the company's proprietary LymphoSIGHT immune repertoire sequencing platform to investigate the effects ...
May 28, 2014
0
0